VIVUS Announces Qnexa R&D Day Event and Live Webcast
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will provide a complete review of the Qnexa development program to investors and analysts on Thursday, December 6, 2007, in New York.
The event will begin at 8:00 a.m. ET and will include a series of presentations by leading obesity practitioners and regulatory experts, as well as management presentations on the progress of Qnexa and detailed plans of the phase 3 development program in obesity.
In addition to VIVUS management, presenters will include:
F. Xavier Pi-Sunyer, M.D., MPH — Professor of Medicine at Columbia University College of Physicians and Surgeons
Louis J. Aronne, M.D., FACP — Clinical Professor of Medicine at Weill-Cornell Medical College
David G. Orloff, M.D. — Medical Director at Medpace Inc.
To access an audio webcast of this event, please visit VIVUS’ Investors site at http://www.vivus.com. Replay will also be available on demand from the website at the conclusion of the program and will run through December 31, 2007.
If you are interested in attending or would like more information on the company, please contact David Warren at the Trout Group at +1 646 378 2932 or dwarren@troutgroup.com.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for the treatment of obesity and phase 2 for the treatment of diabetes; Testosterone MDTS®, for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE® is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company’s web site at http://www.vivus.com.